145 related articles for article (PubMed ID: 6607977)
1. Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate.
Jaffe N; Prudich J; Knapp J; Wang YM; Bowman R; Cangir A; Ayala A; Chuang V; Wallace S
J Clin Oncol; 1983 Jul; 1(7):428-31. PubMed ID: 6607977
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.
Jaffe N; Robertson R; Ayala A; Wallace S; Chuang V; Anzai T; Cangir A; Wang YM; Chen T
J Clin Oncol; 1985 Aug; 3(8):1101-4. PubMed ID: 3874932
[TBL] [Abstract][Full Text] [Related]
3. Control of primary osteosarcoma with chemotherapy.
Jaffe N; Robertson R; Takaue Y; Cangir A; Wallace S; Carrasco H; Eftekhari F; Ayala A; Wang A
Cancer; 1985 Aug; 56(3):461-6. PubMed ID: 3873985
[TBL] [Abstract][Full Text] [Related]
4. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
5. Experimental studies on high-dose methotrexate with citrovorum factor chemotherapy for 89Sr-induced osteosarcoma murine model.
Tomita K
Jpn J Antibiot; 1986 May; 39(5):1219-27. PubMed ID: 3489843
[TBL] [Abstract][Full Text] [Related]
6. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
Nakamura T
Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
[TBL] [Abstract][Full Text] [Related]
7. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
8. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
9. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
Camitta BM; Holcenberg JS
Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
[TBL] [Abstract][Full Text] [Related]
10. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate with a safe rescue program.
Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
Erttmann R; Bielack S; Landbeck G
Cancer Chemother Pharmacol; 1985; 15(2):101-4. PubMed ID: 3874719
[TBL] [Abstract][Full Text] [Related]
13. Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies.
Sasaki K; Tanaka J; Murakami T; Matuoka H; Fujimoto T; Taguchi H
Cancer Drug Deliv; 1985; 2(1):77-86. PubMed ID: 3876873
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.
Jaffe N; Gorlick R
J Clin Oncol; 2008 Sep; 26(27):4365-6. PubMed ID: 18802144
[No Abstract] [Full Text] [Related]
15. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
16. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
Saeter G; Alvegård TA; Elomaa I; Stenwig AE; Holmström T; Solheim OP
J Clin Oncol; 1991 Oct; 9(10):1766-75. PubMed ID: 1717666
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
18. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
[TBL] [Abstract][Full Text] [Related]
19. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
20. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas].
Hayashi A; Kyuma Y
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1461-6. PubMed ID: 2117886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
